Artificial Intelligence
The US National Institute of Standards and Technology (NIST) has evaluated the use of Genomic Vision applications for genetic variant characterization
<!– Name:DistributionId Value:1000783713 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value:4573 –> <!– Name:CustomerId Value:700013487 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:7824067d-0d8e-453e-8a67-40a98308dd54 –>
GENOMICS | CELL & GENE THERAPIES | BIOPRODUCTION
The US National Institute of Standards and Technology (NIST) has evaluated the use of Genomic Vision applications for genetic variant characterization
- Genomic Vision’s technology demonstrated high accuracy for quantitative analysis of genomic events
- This paves the way to establish standardized methods for cell characterization
Bagneux (France) – Genomic Vision (FR0011799907 – GV, the “Company”), a Euronext-listed biotechnology company that develops products and services for the highly accurate characterization of DNA sequences, is pleased to announce the successful evaluation of its DNA combing technology by the US National Institute of Standards and Technology (‘NIST’). The evaluation has confirmed the high accuracy of the technology for quantitative analysis of genomic events at or greater than 10 kilobases.
The NIST Genome Editing Consortium (‘Consortium’) is a public-private partnership consortium hosted by NIST to collaboratively address precompetitive genome editing measurements and standards (reference standards, reference methods, and reference data) needed to increase confidence in evaluating genome editing and utilizing these technologies in research and commercial products.
Within this Consortium, Genomic Vision’s Quality Control Assay (‘QCA’) was employed to identify, characterize, and quantify mid to large-size genomic variants occurring in a specific human population. The results were compiled by NIST and compared to other datasets obtained within the Consortium. NIST determined that Genomic Vision’s technology produced high quality results. The global results issued from the Consortium will be disclosed by NIST in spring 2023.
Genomic Vision’s technology allows for highly sensitive and digitally quantifiable analysis of structural and functional genome modifications and provides a quality control tool for the safety and optimization of engineered cells. The data output enables an unbiased assessment of genetic events through direct visualization of modifications on single DNA molecules.
Aaron Bensimon, Chief Executive Officer of Genomic Vision, commented: “We are pleased that our methodology for the characterization of naturally occurring mutations has received further validation, going through NIST’s rigorous interlaboratory study process blinded to the details about the genomic variants to be detected and performing to high standards. We believe our technology can become a gold standard for structural and functional genome analysis, with potential applications for quality control of cell and gene therapy products and bioproduction.”
Samantha Maragh, Ph.D., Project Leader of the Genome Editing program at NIST, commented: “We are pleased to be working with Genomic Vision, a member of the NIST Genome Editing Consortium, and welcome their innovative QCA method of genome characterization to help advance the genome editing field. For this NIST Genome Editing Consortium Interlab Study, organizations were given a set of blinded qualified samples provided by NIST to assess their technologies. Genomic Vision’s technology demonstrated high accuracy for quantitative analysis of genomic events around 10 kilobases and greater.”
The Consortium numbers more than 40 academic and industrial members and Genomic Vision has been part of the NIST Consortium since 2019.
About Genomic Vision
GENOMIC VISION is a biotechnology company developing products and services dedicated to the structural and functional analysis of genome modifications as well as to the quality and safety control of these modifications, in particular in genome editing technologies and biomanufacturing processes. Genomic Vision proprietary products and services, based on DNA combing technology and artificial intelligence, provide robust quantitative measurements needed for high confidence characterization of DNA alteration in the genome. These products and services are also used for monitoring DNA replication in cells to improve anti-cancerous drugs development. Genomic Vision, based near Paris in Bagneux, is a public company listed in compartment C of Euronext’s regulated market in Paris (Euronext: GV – ISIN: FR0011799907).
For further information, please visit
About the National Institute of Standards and Technology (NIST)
The National Institute of Standards and Technology (NIST) was founded in 1901 and is now part of the U.S. Department of Commerce. NIST is one of the nation’s oldest physical science laboratories, and addresses measurement research needs in multiple fields including chemistry, IT, engineering and biology. The NIST Genome Editing Consortium addresses the measurements and standards needed to increase confidence of utilizing genome editing technologies in research and commercial products (www.nist.gov).
| Genomic Vision Aaron Bensimon CEO Phone: +33 1 49 08 07 51 Email: [email protected] |
Consilium Strategic Communications
International Investor Relations & Strategic Communications Tel: +44 (0) 20 3709 5700 |
| Ulysse Communication
Media Relations Bruno Arabian Tél. : +33 1 42 68 29 70 |
NewCap Investor relations Phone: +33 1 44 71 94 94 Email: [email protected] |
Member of the CAC® Mid & Small and CAC® All-Tradable indices
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain forward-looking statements concerning Genomic Vision and its business. Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the “Risk Factors” section of the universal registration document filed with the AMF on April 14, 2022 under reference number R.22-0293, as updated by the amendment filed with the AMF on May 20, 2022, under number D.22-0293-A01, available on the web site of Genomic Vision (www.genomicvision.com) and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.
This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for Genomic Vision shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.
Artificial Intelligence
Invitation to the presentation of ASSA ABLOY’s Q3 report on 23 October starting at 09:00am (CEST)
STOCKHOLM, Oct. 1, 2024 /PRNewswire/ — ASSA ABLOY will release its Q3 report 2024 on Wednesday 23 October 2024 at 08:00 am (CEST). A conference call and webcast will be held following the release of the results, starting at 09:00 am (CEST) and continuing until 10:00 am (CEST). The presentation will be hosted by Nico Delvaux, President & CEO, and Erik Pieder, CFO, followed by questions and answers.
Slides used during the presentation will be available shortly after the release of the report on our website.
Enter the conference call and download presentation material at:assaabloy.com/investors
The details for participation by telephone are as follows:
Participants in Sweden should call +46 8 5051 00 31Participants in UK/Europe should call +44 207 107 06 13Participants in US should call +1 631 570 56 13Other international numbers available HEREFor more information, please contact:Isabelle Ewerlöf, Investor Relations Officer, tel: +46 8 506 485 74
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/assa-abloy/r/invitation-to-the-presentation-of-assa-abloy-s-q3-report-on-23-october-starting-at-09-00am–cest-,c4044794
The following files are available for download:
https://mb.cision.com/Public/7333/4044794/87a98230b5054c2e.pdf
Q3 invitation
View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-the-presentation-of-assa-abloys-q3-report-on-23-october-starting-at-0900am-cest-302263614.html
TAMPERE, Finland, Oct. 1, 2024 /PRNewswire/ — Treon, a leader in IoT technology launches Treon Connect, a platform designed to tackle challenges in operational technology (OT). Founded by innovators with a background in ‘connecting people,’ Treon has evolved to focus on connecting operations, leveraging its expertise in IoT and data acquisition.
Despite industrial digitalization progress, physical operations still face significant challenges. Treon Connect is built to overcome these obstacles, offering businesses the tools to enhance operational efficiency and sustainability.
“Siloed vertical solutions hinder scalability, increase costs and enforce manual workflows” said Joni Korppi, CEO of Treon. “At Treon, we developed Treon Connect to address these challenges, drawing on our experience in delivering IoT solutions for large-scale deployments with 150+ customers, including 50 global leaders.”
Treon Connect works alongside customers’ existing systems, enabling data-driven automation, and helping organizations improve operations by:
Enhancing efficiency: Reducing operational costs and extending asset lifespan through increased uptime and optimal use.Prioritizing worker safety: Reducing downtime and providing safer, more controlled environments.Seamless integration: Integrates with existing IT and OT systems.Minimizing environmental impact: Sustainable products that cut emissions, boost energy efficiency, and reduce waste.As part of Treon Connect, Treon launches:
Treon Apex applications for Condition Monitoring, Fleet Management, Network & Device Management, and Events for workflow automation.Treon Aito, the middleware that securely bridges applications, databases, and systems, is now available on cloud or on-premise, expanding support to third-party devices.Treon Industrial Node X, Treon’s latest wireless vibration sensor, offering market-leading capabilities, such as support for variable-speed machinery and a replaceable battery for sustainabilityTreon Gateway 2, a powerful edge computer, has been updated with cellular coverage for the USA, and telematics support for heavy equipment.Treon will launch Treon Connect at SMRP Annual Conference, October 7-10, 2024, in Orlando, FL, where they will showcase their latest innovations and continue introducing new use cases to enhance operations at a rapid pace together with ecosystem partners.
Visit treon.fi/treon-connect
About Treon
Treon is a leading technology company with a mission to help businesses improve productivity, enhance operational visibility, and sustainability. Its platform, Treon Connect, boosts operational efficiency by utilizing data-driven automation to extend machine lifespan, monitor assets, increase productivity, and ensure safety across industries. Treon is trusted by global leaders to provide secure, customized products that integrate seamlessly into existing business solutions.
Press inquiries
Samah Zain, Senior Growth [email protected]+358-505507331
Photo – https://mma.prnewswire.com/media/2519329/Treon_Connect.jpgLogo – https://mma.prnewswire.com/media/2519328/Treon_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/breaking-barriers-in-operational-technology-meet-treon-connect-302262739.html
Artificial Intelligence
dsm-firmenich completes the sale of its MEG-3® fish oil business to KD Pharma Group SA
KAISERAUGST, Switzerland and MAASTRICHT, Netherlands, Oct. 1, 2024 /PRNewswire/ — dsm-firmenich, innovators in nutrition, health, and beauty, today announces the successful completion of the sale and transfer of its MEG-3® fish oil business for the Food & Beverage, Dietary Supplement and Pharma markets, together with the production facilities in Piura, Peru and Mulgrave, Canada.
As part of the transaction, dsm-firmenich received a minority stake of 29% in KD Pharma’s parent company MidCo Omega GmbH.
The sale and transfer of the business was announced on July 18, 2024. Financial details of the transaction will not be disclosed.
About dsm-firmenichAs innovators in nutrition, health, and beauty, dsm-firmenich reinvents, manufactures, and combines vital nutrients, flavors, and fragrances for the world’s growing population to thrive. With our comprehensive range of solutions, with natural and renewable ingredients and renowned science and technology capabilities, we work to create what is essential for life, desirable for consumers, and more sustainable for the planet. dsm-firmenich is a Swiss-Dutch company, listed on the Euronext Amsterdam, with operations in almost 60 countries and revenues of more than €12 billion. With a diverse, worldwide team of nearly 30,000 employees, we bring progress to life every day, everywhere, for billions of people. www.dsm-firmenich.com
For more information
Media relationsRobin Roothanstel. +41 (0)79 280 03 96e-mail [email protected]
Investor relationsDave Huizingtel. +31 (0)88 425 7306e-mail [email protected]
Forward-looking statementsThis press release may contain forward-looking statements with respect to dsm-firmenich’s future (financial) performance and position. Such statements are based on current expectations, estimates and projections of dsm-firmenich and information currently available to the company. dsm-firmenich cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. dsm-firmenich has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.
Logo – https://mma.prnewswire.com/media/2071772/dsm_firmenich_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/dsm-firmenich-completes-the-sale-of-its-meg-3-fish-oil-business-to-kd-pharma-group-sa-302262469.html
-
Artificial Intelligence4 days agoCluePoints Launches Medical & Safety Review (MSR) Software to Revolutionize Clinical Data Review
-
Uncategorized4 days agoMC Digital Realty wins Frost & Sullivan’s 2024 Japan Data Center Services Company of the Year Award
-
Artificial Intelligence4 days agoHyperlink InfoSystem Takes the Spotlight as a Top AI Development Company in USA 2024
-
Uncategorized4 days ago
Prime Minister concludes successful visit from President of France to Canada
-
Artificial Intelligence4 days agoHow AIoT shapes the future of mobility: Hikvision at ITS World Congress 2024
-
Artificial Intelligence4 days agoWondershare to Showcase Enterprise Solution Excellence at GITEX GLOBAL 2024
-
Artificial Intelligence7 days agoNetcore Cloud appoints former McKinsey Partner, Siddharth Gopalkrishnan as Chief Operating Officer (COO) to fuel global expansion
-
Uncategorized4 days ago
Relativity Spotlights Legal Industry Leaders at the 2024 Innovation Awards
